AbbVie Inc (ABBV)vsQuanterix Corp (QTRX)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
QTRX
Quanterix Corp
$3.13
+2.62%
HEALTHCARE · Cap: $157.20M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 43933% more annual revenue ($61.16B vs $138.90M). ABBV leads profitability with a 6.9% profit margin vs -77.1%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
QTRX
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+83.2%
Fair Value
$34.95
Current Price
$3.13
$31.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.7% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : QTRX
The strongest argument for QTRX centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : QTRX
The primary concerns for QTRX are EPS Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while QTRX is a growth play — different risk/reward profiles.
QTRX carries more volatility with a beta of 1.32 — expect wider price swings.
QTRX is growing revenue faster at 24.7% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 42/100). QTRX offers better value entry with a 83.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Quanterix Corp
HEALTHCARE · MEDICAL DEVICES · USA
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advance precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the regions from Asia Pacific. The company is headquartered in Billerica, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?